ABVC BioPharma (NASDAQ:ABVC) Trading Up 0.4% – What’s Next?

Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) were up 0.4% during mid-day trading on Friday . The stock traded as high as $0.66 and last traded at $0.64. Approximately 199,668 shares changed hands during trading, a decline of 60% from the average daily volume of 500,786 shares. The stock had previously closed at $0.64.

ABVC BioPharma Trading Up 0.4 %

The stock has a market cap of $8.29 million, a PE ratio of -0.74 and a beta of 0.67. The company has a fifty day moving average of $0.57 and a 200-day moving average of $0.58.

Institutional Investors Weigh In On ABVC BioPharma

An institutional investor recently raised its position in ABVC BioPharma stock. Avantax Planning Partners Inc. lifted its position in ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the quarter. Avantax Planning Partners Inc. owned approximately 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.